Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Clinical Trials Related to Cemiplimab
Related studies linked through entity extraction aliases.
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Cemiplimab in Adults With Cervical Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2